Literature DB >> 3298694

Single course versus maintenance bacillus Calmette-Guerin therapy for superficial bladder tumors: a prospective, randomized trial.

M A Hudson, T L Ratliff, D P Gillen, E O Haaff, S M Dresner, W J Catalona.   

Abstract

A total of 42 patients with recurrent superficial bladder tumors or carcinoma in situ entered a prospective, randomized trial to compare the efficacy of bacillus Calmette-Guerin therapy with and without quarterly maintenance instillations of bacillus Calmette-Guerin. Maintenance therapy did not reduce further bladder tumor recurrence rates or the interval to recurrence in patients who responded to the initial course of therapy. However, prolongation of toxicity was observed with maintenance bacillus Calmette-Guerin therapy.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3298694     DOI: 10.1016/s0022-5347(17)43125-9

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  23 in total

Review 1.  New Strategies in Bladder Cancer: A Second Coming for Immunotherapy.

Authors:  Ali Ghasemzadeh; Trinity J Bivalacqua; Noah M Hahn; Charles G Drake
Journal:  Clin Cancer Res       Date:  2015-12-18       Impact factor: 12.531

2.  Intravesical bacillus Calmette-Guérin administration in the prophylaxis of superficial bladder cancer.

Authors:  M D Melekos; A Pantazakos; S Markou; C Skopa; A Athanassopoulos; G Barbalias
Journal:  Int Urol Nephrol       Date:  1990       Impact factor: 2.370

Review 3.  Tumors of the kidney, ureter, and bladder.

Authors:  W A See; R D Williams
Journal:  West J Med       Date:  1992-05

Review 4.  Intravesical therapy for urothelial carcinoma of the urinary bladder: a critical review.

Authors:  Daher C Chade; Shahrokh F Shariat; Guido Dalbagni
Journal:  Int Braz J Urol       Date:  2009 Nov-Dec       Impact factor: 1.541

Review 5.  Immune therapies in non-muscle invasive bladder cancer.

Authors:  Philip L Ho; Stephen B Williams; Ashish M Kamat
Journal:  Curr Treat Options Oncol       Date:  2015-02

Review 6.  Medical management of patients with refractory carcinoma in situ of the bladder.

Authors:  J C Kim; G D Steinberg
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 7.  Immunobiology and immunotherapy in genitourinary malignancies.

Authors:  Marinos Tsiatas; Petros Grivas
Journal:  Ann Transl Med       Date:  2016-07

8.  Monthly intravesical bacillus Calmette-Guérin maintenance therapy for non-muscle-invasive bladder cancer: 10-year experience in a single institute.

Authors:  Koo Han Yoo; Tae Joon Lim; Sung-Goo Chang
Journal:  Exp Ther Med       Date:  2011-12-01       Impact factor: 2.447

9.  Myths and mysteries surrounding bacillus Calmette-Guérin therapy for bladder cancer.

Authors:  Ashish M Kamat; Sima Porten
Journal:  Eur Urol       Date:  2013-10-26       Impact factor: 20.096

10.  Intravesical combination chemotherapy with mitomycin C and doxorubicin for superficial bladder cancer: a randomized trial of maintenance versus no maintenance following a complete response.

Authors:  I Fukui; K Kihara; H Sekine; Y Tachibana; T Kawai; D Ishiwata; H Oshima
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.